Announcement • Mar 10
JLK, Inc., Annual General Meeting, Mar 27, 2026 JLK, Inc., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 45, myeongam-ro 293beon-gil, sangdang-gu, chungcheongbuk-do, cheongju South Korea New Risk • Dec 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩3.3b revenue, or US$2.2m). New Risk • Oct 13
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩138.0b (US$96.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 7.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩2.6b revenue, or US$1.8m). Market cap is less than US$100m (₩138.0b market cap, or US$96.8m). New Risk • Aug 20
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩138.0b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 4.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩1.8b revenue, or US$1.3m). Market cap is less than US$100m (₩138.0b market cap, or US$98.7m). Announcement • Jul 04
JLK,Inc. announced that it has received KRW 11.9 billion in funding from Shinhan Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd., Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd., KB Securities Co., Ltd. On July 2, 2025, JLK,Inc closed the transaction. New Risk • Mar 28
New major risk - Revenue and earnings growth Earnings have declined by 1.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 1.6% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Revenue is less than US$1m (₩1.4b revenue, or US$974k). Announcement • Mar 01
JLK,Inc., Annual General Meeting, Mar 28, 2025 JLK,Inc., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: seminar room, 45, myeongam-ro 293beon-gil, sangdang-gu, chungcheongbuk-do, cheongju South Korea New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (₩1.6b revenue, or US$1.1m). New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (32% increase in shares outstanding). New Risk • Nov 08
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 32% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Shareholders have been diluted in the past year (32% increase in shares outstanding). Revenue is less than US$5m (₩1.6b revenue, or US$1.2m). Reported Earnings • Mar 26
Full year 2023 earnings released: ₩469 loss per share (vs ₩605 loss in FY 2022) Full year 2023 results: ₩469 loss per share (improved from ₩605 loss in FY 2022). Revenue: ₩2.49b (down 27% from FY 2022). Net loss: ₩7.32b (loss narrowed 19% from FY 2022). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 15
JLK Inc. Unveils Its AI-Powered Imaging Diagnosis Solutions for Stroke JLK Inc. reveals its ambition to dominate US healthcare market with one of the world's largest number of AI-powered advanced imaging diagnosis solutions for stroke. JLK's advanced technology is compatible with all medical imaging devices, including CT, MRI, CTA, and MRA, essential for brain-related diagnoses. Their lightweight AI algorithms enable real-time diagnostic capabilities, setting them apart in the medical tech landscape. JLK's entry into the US is currently preparing FDA applications. By 2024, the company aims not only to be an active player in the US healthcare field but also to secure insurance reimbursements. For this reason, JLK already holds patents related to their innovative solutions. As the elderly population across the globe is steadily increasing, stroke disease is a severe and frequent disease with more than 15 million new patients worldwide every year. The global stroke market also grows by 8% annually, and the medical AI market is expected to grow to about 190 million dollars by 2030. Compared to other diseases, there are no biomarkers, and as an acute disease, the stroke field is considered one of the markets that desperately need help from healthcare AI. Rapid AI in the United States, Viz.ai in Israel, and JLK in South Korea are AI Diagnosis Stroke Global Leading 3 Companies. Stroke is one of the most difficult diagnostic areas, and it is characterized by not having many competitors in the world. Rapid AI, founded in 2012 and headquartered in California, USA, is a company that develops stroke diagnosis and imaging software through artificial intelligence. Viz.AI is an Israeli company entered into partnerships with large hospitals in the United States to deploy stroke imaging solutions. Both companies have been approved by the FDA and applied to medical insurance in the United States. Also they created remarkable sales in 2022. Many experts predict that the stroke-related AI medical market will show explosive growth in the US healthcare field when JLK joins the US market with various types of stroke solutions compared to its competitors. The healthcare market looks forward to protecting people's lives by applying AI to medical care. Is New 90 Day High Low • Jan 18
New 90-day low: ₩9,420 The company is down 24% from its price of ₩12,450 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is down 7.0% over the same period. Is New 90 Day High Low • Dec 28
New 90-day low: ₩9,500 The company is down 28% from its price of ₩13,250 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is down 9.0% over the same period. Is New 90 Day High Low • Dec 08
New 90-day low: ₩10,400 The company is down 4.0% from its price of ₩10,800 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare Services industry, which is down 8.0% over the same period. Is New 90 Day High Low • Sep 18
New 90-day high: ₩14,150 The company is up 91% from its price of ₩7,420 on 19 June 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 20% over the same period. 